A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe

IlDong Pharmaceutical

Status: Not yet enrolling

Conditions: Mixed Dyslipidemia

Treatments: Other: NA (Observation study)

Study type: Observational

Funder types: Industry

Identifiers

NCT03648788

ID-DRT-401

Details and patient eligibility

About

Post-marketing surveillance of Rosuvastatin/Ezetimibe

Full description

This study will collect clinical data, mainly focused on safety, in Korean population as per the requirement of MFDS for market authorization.

Enrollment: 600 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient who is first prescribed and administered Rosuvastatin/Ezetimibe

Exclusion criteria

• The patients who are overreacting to this drug or its components
• The patients with severe renal impairment